Paraneoplastic Syndromes Case 2 Abbas Agaimy, MD University of - - PowerPoint PPT Presentation

paraneoplastic
SMART_READER_LITE
LIVE PREVIEW

Paraneoplastic Syndromes Case 2 Abbas Agaimy, MD University of - - PowerPoint PPT Presentation

Paraneoplastic Syndromes Case 2 Abbas Agaimy, MD University of Erlangen, Germany abbas.agaimy@uk-erlangen.de The main message of the cases is to demonstrate how paraneoplasia was a key to correctly recognize and properly classify the


slide-1
SLIDE 1

Abbas Agaimy, MD University of Erlangen, Germany abbas.agaimy@uk-erlangen.de

Paraneoplastic Syndromes Case 2

slide-2
SLIDE 2

The main message of the cases is to demonstrate how paraneoplasia was „a key“ to correctly recognize and properly classify the neoplasm under consideration

slide-3
SLIDE 3
  • 39 yo male.
  • Heart transplantation 40 months ago.
  • Uneventful follow-up with endomyocardial biopsies.
  • Admitted with rapid worsening of general condition.
  • EMB: no evidence of acute graft rejection.

Agaimy , Case #2

slide-4
SLIDE 4

Unexplained hypercalcemia of 4.0 mmol/l (reference range, 2.1 to 2.7 mmol/l)

slide-5
SLIDE 5

Normal parathyroid function. Serum parathyroid hormone-related protein (PTHrp) significantly elevated (241 pg/ml; reference value <57).

slide-6
SLIDE 6

Multiple irregular liver nodules

CT abdomen+thorax:

  • Multiple enlarged

mediastinal, hilar and para-aortic lymph nodes.

  • Multiple liver nodules.
  • Core needle biopsies
  • btained from a liver

nodule.

slide-7
SLIDE 7

Despite maximum interdisciplinary therapy, the patient died of supervening multi-organ failure within one week. An autopsy was not performed.

slide-8
SLIDE 8

Liver biopsy: Large epithelioid cells In nests and abortive gland-like pattern

slide-9
SLIDE 9

Scattered rhabdoid inclusions

slide-10
SLIDE 10

brisk mitotic activity

slide-11
SLIDE 11

AE1/AE3 CK20 Dot-like „rhabdoid“ pattern

slide-12
SLIDE 12

CK7- HepPar1-

  • GATA3 & SATB2 focal +
  • MMR intact
  • Poorly difreentaited carcinoma with

rhabdoid cell features

  • IHC suggestive of GI tract origin
slide-13
SLIDE 13

80% 20% <1% <1% Affects 44% of patients with cancer, usually those with advanced disease Humoral type: Peptides secreted by tumor (80% of cases):

  • PTH-rP (ectopic)
  • 1,25 vit D (ectopic)
  • PTH (PT or ectopic)

Secondary type (20%): Increased bone metabolism due to mets

slide-14
SLIDE 14

Paraneoplastic hypercalcemia (PNH)

Tumors reported to be associated with PNH

  • Small cell carcinoma of the ovary hypercalcemic type

(SCCOHT): up to 75% of cases display PNH.

  • Most of human T-cell lymphotrophic virus type I (HTLV-I)-

associated adult T-cell leukemia/lymphoma (ATL).

  • Diverse carcinoma types.
  • GI stromal tumors (6 reported cases).
slide-15
SLIDE 15

Paraneoplastic hypercalcemia (PNH)

Tumors reported to be associated with PNH

  • Small cell carcinoma of the ovary hypercalcemic type

(SCCOHT): up to 75% of cases display PNH.

  • Most of human T-cell lymphotrophic virus type I (HTLV-I)-

associated adult T-cell leukemia/lymphoma (ATL).

  • Diverse carcinoma types.
  • GI stromal tumors (6 reported cases).
slide-16
SLIDE 16
  • Age range:9-43 yrs (mean, 24)
  • 99% unilateral
  • Hypercalcemia in 62%-75%
  • Extraovarian spread: 50%
slide-17
SLIDE 17

Small cell carcinoma of

  • vary, classical type

Follicle-like spaces simulating juvenile granulosa cell tumor

slide-18
SLIDE 18

Our case

  • Large rhabdoid cells present in 50%:
  • Minor in 25%
  • Moderate in 16%
  • Predominated in 12%

(=so-called large cell variant)

SCCOHT

slide-19
SLIDE 19

SMARCA4

slide-20
SLIDE 20

SMARCA4 SMARCA2

Our case

slide-21
SLIDE 21
slide-22
SLIDE 22

SMARCA4: a core subunit of the SWI/SNF chromatin remodelling complex

SMARCA4 loss (inactivation) in:

  • SCCOHT (100%)
  • Subsets of pediatric AT/RTs (2%)
  • Undifferentiated thoracopulmonary malignancies (100%)
  • 5-10% of NSCLC
  • Subset of sinonasal undiff carcinomas (rare)
  • Subset of dedifferentiated carcinomas:
  • GI tract
  • Uterus
  • Kidney
  • Bladder
slide-23
SLIDE 23

Do not ask how a neoplasm look-alike but ask why it looks alike.

Juan Rosai, MD

Any questions?